{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:05:48Z","timestamp":1784588748062,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"NIDA","award":["P50-09241"],"award-info":[{"award-number":["P50-09241"]}]},{"name":"K01-DA","award":["039299"],"award-info":[{"award-number":["039299"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.drugalcdep.2018.08.019","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T12:41:15Z","timestamp":1538656875000},"page":"264-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder"],"prefix":"10.1016","volume":"192","author":[{"given":"Kathleen M.","family":"Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charla","family":"Nich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami L.","family":"Frankforter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Kiluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise E.","family":"DeVito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Sofuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jad.2014.09.013","article-title":"Rating scales in general practice depression: psychometric analyses of the clinical interview for depression and the Hamilton rating scale","volume":"171","author":"Bech","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time course","volume":"123","author":"Bigelow","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jsat.2014.01.005","article-title":"A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence","volume":"46","author":"Bisaga","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/archpsyc.58.8.755","article-title":"2001. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement","volume":"58","author":"Carroll","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0035","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/npp.2013.143","article-title":"Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers","volume":"38","author":"Comer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/08897077.2015.1052868","article-title":"A demonstration project implementing extended-release naltrexone in Los Angeles County","volume":"37","author":"Cousins","year":"2016","journal-title":"Subst. Abuse"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1521-0391.2010.00070.x","article-title":"A randomized trial of oral naltrexone for treating opioid-dependent offenders","volume":"19","author":"Coviello","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/bjsm.26.2.111","article-title":"Opiate receptor blockade by naltrexone and mood state after acute physical activity","volume":"26","author":"Daniel","year":"1992","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1139\/jpn.0605","article-title":"Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence","volume":"31","author":"Dean","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1017\/S0033291700048017","article-title":"The brief symptom inventory: an introductory report","volume":"13","author":"Derogatis","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0065","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0070","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/ADM.0000000000000302","article-title":"Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence","volume":"11","author":"Earley","year":"2017","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0075","series-title":"Structured Clinical Interview for DSM-IV, Patient Edition","author":"First","year":"1995"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2017.04.010","article-title":"Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison","volume":"85","author":"Friedmann","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsat.2017.01.018","article-title":"Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?","volume":"85","author":"Friedmann","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/09595230701373834","article-title":"Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records","volume":"26","author":"Gibson","year":"2007","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsat.2015.07.005","article-title":"A Phase 4, pilot, open-label study of VIVITROL(R) (Extended-Release Naltrexone XR-NTX) for prisoners","volume":"59","author":"Gordon","year":"2015","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0376-8716(81)90084-3","article-title":"Aversive effects of naltrexone in subjects not dependent on opiates","volume":"8","author":"Hollister","year":"1981","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.brainresbull.2015.12.004","article-title":"Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence","volume":"123","author":"Huhn","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0110","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0115","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1360-0443.2012.03910.x","article-title":"Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use","volume":"107","author":"Kelty","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0120","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1360-0443.2002.00217.x","article-title":"A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence","volume":"97","author":"Kirchmayer","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0125","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/00952990.2016.1197231","article-title":"Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant","volume":"42","author":"Krupitsky","year":"2016","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/dar.12095","article-title":"A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence","volume":"33","author":"Larney","year":"2014","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0135","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsat.2017.04.002","article-title":"Extended-release naltrexone for opioid use disorder started during or following incarceration","volume":"85","author":"Lincoln","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0150","doi-asserted-by":"crossref","first-page":"41952","DOI":"10.1038\/srep41952","article-title":"Anhedonia to music and mu-opioids: evidence from the administration of naltrexone","volume":"7","author":"Mallik","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0306-4530(78)90013-6","article-title":"Effects of naltrexone on mood and neuroendocrine function in normal adult males","volume":"3","author":"Mendelson","year":"1978","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0376-8716(97)01348-3","article-title":"Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts","volume":"45","author":"Miotto","year":"1997","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0165","first-page":"151","article-title":"Naltrexone and dysphoria: fact or myth? Am","volume":"11","author":"Miotto","year":"2002","journal-title":"J. Addict."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00952990.2010.540281","article-title":"The association between naltrexone treatment and symptoms of depression in opioid-dependent patients","volume":"37","author":"Mysels","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0180","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","article-title":"Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): who will respond?","volume":"9","author":"Nunes","year":"2015","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0185","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-127-7-199710010-00004","article-title":"Three methods of opioid detoxification in a primary care setting. A randomized trial","volume":"127","author":"O\u2019Connor","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0190","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0195","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1017\/S1461145711001830","article-title":"Naltrexone does not attenuate the effects of intravenous Delta9-tetrahydrocannabinol in healthy humans","volume":"15","author":"Ranganathan","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0205","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00213-011-2425-y","article-title":"Protracted manifestations of acute dependence after a single morphine exposure","volume":"219","author":"Rothwell","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0210","series-title":"Potentiating the Efficacy of Medications: Integrating Psychosocial Therapies with Pharmacotherapies in the Treatment of Drug Dependence","first-page":"37","article-title":"Can psychotherapy rescue naltrexone treatment of opioid addiction?","author":"Rounsaville","year":"1995"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00005053-198502000-00007","article-title":"Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal","volume":"173","author":"Rounsaville","year":"1985","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0220","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002139900358","article-title":"Opiate withdrawal-induced place aversion lasts for up to 16 weeks","volume":"149","author":"Stinus","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugalcdep.2014.11.028","article-title":"Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone","volume":"147","author":"Sullivan","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0235","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(17)32893-3","article-title":"Medications for opioid use disorder: bridging the gap in care","volume":"391","author":"Volkow","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0245","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0376-8716(99)00127-1","article-title":"Naltrexone does not block the subjective effects of oral \u03949-tetrahydrocannabinol in humans","volume":"59","author":"Wachtel","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0250","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/17470919.2015.1136355","article-title":"Naltrexone alters the processing of social and emotional stimuli in healthy adults","volume":"11","author":"Wardle","year":"2016","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.drugalcdep.2018.08.019_bib0255","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ajad.12527","article-title":"Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders","volume":"26","author":"Williams","year":"2017","journal-title":"Am. J. Addict."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618306665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618306665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:59:37Z","timestamp":1759827577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618306665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":51,"alternative-id":["S0376871618306665"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.019","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}